Daniele Caracciolo

Catanzaro, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

Journal: British journal of haematology

Published: April 19, 2026

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

Journal: British journal of haematology

Published: March 12, 2026

Regional Standardization of CLL Management: Results of a Delphi Consensus Process.

Regional Standardization of CLL Management: Results of a Delphi Consensus Process.

Journal: European journal of haematology

Published: March 03, 2026

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Journal: Hematological oncology

Published: October 18, 2025

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Journal: Blood advances

Published: October 15, 2025

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Journal: Blood advances

Published: October 15, 2025

UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager.

UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager.

Journal: Hematological oncology

Published: September 24, 2025

PARP1 trapping activates cGAS-STING pathway to induce immunogenic cell death in multiple myeloma.

PARP1 trapping activates cGAS-STING pathway to induce immunogenic cell death in multiple myeloma.

Journal: Cancer cell international

Published: September 10, 2025

CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy.

CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy.

Journal: Cancers

Published: July 19, 2025

Endoscopic Progression of Gastric DLBCL in an HIV-Positive Patient: A Case Report and Literature Review.

Endoscopic Progression of Gastric DLBCL in an HIV-Positive Patient: A Case Report and Literature Review.

Journal: Reviews on recent clinical trials

Published: March 23, 2025

Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma.

Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma.

Journal: Journal of clinical medicine

Published: March 16, 2025

Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase.

Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase.

Journal: Cancer medicine

Published: March 06, 2025

Showing 1-12 of 77

Last Updated: 09/26/2026